Pleural Mesothelioma

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.

Read More »

Doctors Will Soon be Able to Test if Surgery is Safe for Mesothelioma Patients

Doctors could soon know if surgery is the best option for mesothelioma patients. Surgery is one of the most effective ways to improve patients’ lives. The problem is that undergoing surgery is very stressful on people’s bodies, especially when they have cancer. It is better to know if surgery can[…]

Read More »

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)

There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.

Read More »

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study

This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Drugs used in chemotherapy, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.

Read More »

Pain Shows the Success or Failure of a Pleurodesis

Mesothelioma is a painful cancer that is caused by asbestos exposure. Patients who are diagnosed must live with multiple uncomfortable symptoms, but thankfully there are some treatments available to help improve a patient’s quality of life. One of these procedures is a pleurodesis, which helps to drain fluid surrounding the[…]

Read More »

Shorter Survival for Mesothelioma Patients Linked to Specific Biomarker

Mesothelioma is a very aggressive cancer with a poor prognosis. When diagnosed, patients can sometimes be given just a few months to live.  Doctors and researchers are continuing to find treatment options to help cure, extend, or at least make patients’ lives better. Some researchers are looking at biomarkers, which[…]

Read More »

Upcoming Mesothelioma Events in 2020

If you are interested in learning more about mesothelioma, we have a curated list of different events coming up in 2020. If you live near or are able to travel to these events, they can help you and your loved ones understand the disease better. Mayo Clinic Radiation Oncology: Current[…]

Read More »

Extrapleural Pneumonectomy vs Pleurectomy and Decortication

There are different procedures to help those suffering from mesothelioma, including the extrapleural pneumonectomy and the combination of pleurectomy and decortication. Both procedures have their benefits and drawbacks, but doctors have not tested to see which procedure has a better outcome for patients. Both surgeries remove tumors from the patients’[…]

Read More »

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM. This study will recruit up to 18 patients whose MPM has progressed beyond first-line of palliative chemotherapy, with a platinum-based doublet, and now requires further palliative systemic treatment, or have declined first-line palliative chemotherapy, however must have been considered suitable for a platinum doublet chemotherapy.

Read More »